IPO Archives · BioBuzz

Arcellx Announces Pricing of Initial Public Offering

Published on : February 4, 2022 Published by : BioBuzz Media

GAITHERSBURG, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) – Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the pricing of its initial public offering of 8,250,000 shares of common stock at a public offering price of $15.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expe

Context Therapeutics Doses First Patient in Breast Cancer Trial

Published on : October 28, 2021October 28, 2021 Published by : Alex Keown

Coming off a $28.75 million initial public offering last week, Context Therapeutics dosed its first patient in a mid-stage breast cancer study assessing the combination of the progesterone receptor ONA-XR in combination with an estrogen receptor antagonist.

Philadelphia biopharm firm Context Therapeutics files plans for IPO

Published on : September 21, 2021September 21, 2021 Published by : Chris Frew

Another local life sciences company is looking to go public.
Context Therapeutics, a Philadelphia biopharmaceutical company focused on women’s cancers, is seeking to raise about $20 million through its IPO.
In documents filed Monday with the Securities and Exchange Commission, Context states it intends to sell 1.5 shares million of its common stock to the public at $12 to $14 per share.
The company is poised to become the fifth Philadelphia-area life sciences to complete an IPO this year. That distinction, however, could go to Castle Creek Biosciences, a cell and gene therapy company based in Exton that filed plans to go public through a $100 million IPO in July. Neither company has set a specific date for their public offering.
Context plans to list its stock on Nasdaq under the symbol “CNTX.”

Gain Raises $40 Million in IPO, Funds Will Advance Rare Disease Pipeline

Published on : March 19, 2021May 6, 2022 Published by : Alex Keown

Gain Therapeutics made its debut on the Nasdaq Thursday with a $40 million initial public offering. The company will use the funds to advance the development of its pipeline of therapeutics for rare genetic diseases characterized by protein misfolding.

Bethesda’s Gain Therapeutics Announces Pricing of IPO of Common Stock

Published on : March 18, 2021March 18, 2021 Published by : BioBuzz Media

Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock BETHESDA, Md., March 18, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain”) today announced the pricing of its initial [….]

Germantown’s Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock

Published on : January 22, 2021January 22, 2021 Published by : BioBuzz Media

$7.50 per share

5 Questions with Brian Hahn, Senior Vice President & CFO, GlycoMimetics

Published on : October 9, 2020October 13, 2020 Published by : Andy Eckert

Mr. Hahn has more than 15 years of senior financial and operations experience in emerging organizations. He joined GlycoMimetics in 2010. Previously, Mr. Hahn served as executive director of finance at Middlebrook Pharmaceuticals (formerly Advancis Pharmaceutical), a publicly-traded specialty pharmaceutical company.